Breaking Finance News

A statement released earlier today by Canaccord Genuity about Alere (NYSE:ALR) lowers the target price to $53.00

Yesterday Alere (NYSE:ALR) traded -0.19% lower at $43.03. ALR’s 50-day average is $41.36 and its 200-day moving average is $42.85. With the last close up 0.63% from the 200-day moving average, compared with the S&P 500 Index which has decreased -0.01% over the same time. 98,513 shares of Alere exchanged hands, down from an average trading volume of 1,116,490

Alere (NYSE:ALR) had its stock price target reduced to $53.00 by Canaccord Genuity in a report issued Thursday September 29, 2016. The new target price indicates a potential upside of 0.23% from the company's previous stock price.

Recent Performance Chart

Alere (NYSE:ALR)

Alere has a with a one year low of $31.47 and a one year high of $54.13 The company’s market cap is currently $0.

Also covering Alere's price target, a total of 6 analysts have issued a research note on the company. The average target is $54.00 with 0 firms rating the stock a strong buy, zero equity analysts rating the company a buy, seven brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 firms rating the stock a sell.

More About Alere (NYSE:ALR)

Alere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *